Table 1.
Baseline characteristics of the study population.
| AIIRD Patients (n = 463) | Controls (n = 55) | p-Value | ||
|---|---|---|---|---|
| Age (Mean ± SD) | 58.1 ± 14.6 | 52.0 ± 14.4 | 0.003 | |
| Sex (Female) N, % | 72.8% (n = 337) | 69.1% (n = 38) | 0.562 | |
| Diagnosis | RA | 37.6% (n = 174) | N/A | |
| PsA | 22.0% (n = 102) | N/A | ||
| AS | 9.1% (n = 42) | N/A | ||
| SLE | 12.1% (n = 56) | N/A | ||
| SSCL | 5.4% (n = 25) | N/A | ||
| Vasculitis | 9.7% (n = 45) | N/A | ||
| IIM | 3.7% (n = 17) | N/A | ||
| SS | 0.2% (n = 1) | N/A | ||
| IGG4-RD | 0.2% (n = 1) | N/A | ||
| AIIRD Medications | NSAIDs | 2.2% (n = 10) | N/A | |
| GCS | 18.8% (n = 87) | N/A | ||
| HCQ | 17.7% (n = 82) | N/A | ||
| MTX | 28.3% (n = 131) | N/A | ||
| SSZ | 2.2% (n = 10) | N/A | ||
| LEF | 4.5% (n = 21) | N/A | ||
| AZA | 3.9% (n = 18) | N/A | ||
| MMF | 5.0% (n = 23) | N/A | ||
| ANTI-TNF | 23.1% (n = 107) | N/A | ||
| ANTI-IL-6 | 5.8% (n = 27) | N/A | ||
| ANTI-IL-23 | 0.9% (n = 4) | N/A | ||
| ANTI-IL17 | 5.8% (n = 27) | N/A | ||
| ANTI-CD20 * | 16.0% (n = 74) | N/A | ||
| BEL | 1.9% (n = 9) | N/A | ||
| ABT | 2.6% (n = 12) | N/A | ||
| PDE4 | 0.9% (n = 4) | N/A | ||
| JAK-I | 6.5% (n = 30) | N/A | ||
| IVIG | 1.5% (n = 7) | N/A | ||
| COLCHICINE | 1.1% (n = 5) | N/A | ||
| DMARDs by category | cDMARDs | 38.9% (n = 180) | N/A | |
| bDMARDs | 56.2% (n = 260) | N/A | ||
| tsDMARDs | 7.3% (n = 34) | N/A | ||
| Third vaccination | Yes | 99.5% (n = 405 **) | 98.2% (n = 54) | 0.317 |
| Any new autoantibody positivity after second vaccine dose | Yes | 4.0% (n = 18/453 with available data) | 5.6% (n = 3/54 with available data) | 0.481 |
| Any new autoantibody positivity after third vaccine dose | Yes | 8.7% (n = 31/355 with available data) | 0% (n = 0/32 with available data) | 0.094 |
Abbreviations: ABT = abatacept, AIIRD = autoimmune rheumatic disease, anti-IL = anti-interleukin, anti-TNF = anti-tumor necrosis alpha, SSCL: classification criteria for systemic sclerosis, AS = ankylosing spondylitis, AZA = azathioprine, BEL = belimumab, DMARDs = disease-modifying anti-rheumatic drugs, GCS = glucocorticosteroids, HCQ = hydroxychloroquine, IGG4-RD = immonoglobulin G4-related disease, IIM = inflammatory myositis, JAK-I = janus kinase inhibitors, LEF = leflunomide, MMF = mycophenolate mofetil, MTX = methotrexate, n = number, NSAIDs = non-steroidal anti-inflammatory drugs, PsA = psoriatic arthritis, RA = rheumatoid arthritis, SD = standard deviation, SLE = systemic lupus erythematosus, SS = Sjogren’s syndrome, SSZ = sulfasalazine. * Patients on anti-CD20 therapy received their BNT162b2 vaccinations 5 months following their last infusion and 1 month prior to their next infusion. ** A total of 407 patients had data regarding their 3rd vaccine dose.